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Purpose: To evaluate the effects of four different prostate cancer treatments on quality of life (QoL) and patient satisfaction.
Methods: Ninety-six prostate cancer patients were treated with hormone therapy, radical retropubic prostatectomy, high dose rate 
brachytherapy, or low dose rate brachytherapy. We assessed general, cancer-specific, and prostate disease-specific QoL. More than one 
year since commencement of treatment, the patients were asked the following questions: 1) How do you feel about your treatment? 
2) Would you undergo the same treatment again? 
Results: The comparison of baseline and 12-month results showed that general and cancer-specific QoL had changed little in all 
groups. At baseline, the general and cancer-specific QoL tended to be lower in the hormone therapy patients. In the radical the 
retropubic prostatectomy patients, all scores on the Medical Outcomes Study 36-Item Short Form were worse than the baseline 
scores at three months. Scores for the International Index of Erectile Function-5 had also worsened, with no recovery. In the low-dose 
rate brachytherapy patients, the prostate disease-specific QoL at baseline tended to improve. However, the satisfaction levels for each 
treatment were reasonably good, and most patients would choose the same treatment again. 
Conclusions: The results of each of the four treatments differed in assessments of QoL. In the radical retropubic prostatectomy 
patients, the decrease in the International Index of Erectile Function-5 scores was especially remarkable and did not show recovery. 
In contrast, both brachy therapy groups had attained superior sexual function. However, regardless of the quality of life evaluations, 
most patients surveyed were satisfied with their treatments and would choose the same treatment again.
Keywords: Prostate neoplasms, Quality of life, Treatment satisfaction, Prospective longitudinal comparative study
Prostate Int 2013;1(3):117-124 • http://dx.doi.org/10.12954/PI.13021
Original Article
Corresponding author: Sotaro Miwa
Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences, 920-8640 13-1 Takaramachi, Kanazawa, 
Ishikawa, Japan 
E-mail: sotaro@oregano.ocn.ne.jp, Tel: +81-76-265-2393, Fax: +81-76-222-6726
Submitted: 5 July 2013 / Accepted after revision: 27 August 2013
INTRODUCTION
Many treatment options are available for prostate cancer (PCa). 
In cases where the PCa is localized, especially in the low risk 
group, the treatment outcomes of radical retropubic prostatec-
tomy (RRP) and some types of brachytherapy (BT) are excel-
lent regarding long-term survival is concerned [1]. Moreover, 
data in our previous study indicated that hormone therapy 
(HT) is useful for long-term survival in cases where low T stage, 
low grade Gleason score (GS), and low prostate-specific anti-
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gen (PSA) are present [2].
 Health-related quality of life (HRQoL) has become a very 
important factor in patients’ decisions about treatment op-
tions. However, it is still hard to factor HRQoL in decisions 
about treatment because there is still relatively little infor-
mation available comparing HRQoL factors in various PCa 
treatment options. On the other hand, for both patients and 
doctors, patient satisfaction with treatment also seems to be 
an important factor in evaluating the best possible treatment 
option.
 This study was performed to identify and compare varia-
tions in HRQoL developing over a timeline extending from 
baseline to one year after treatment. The satisfaction of the 
surveyed patients at more than one year following the com-
mencement of treatment was evaluated. To our knowledge, 
this is the first report comparing the effects of four different 
PCa treatments during the same period at one institution.
MATERIALS AND METHODS
Between January 2006 and June 2008, 96 men diagnosed with 
PCa were treated with HT, RRP, and high dose rate BT (HDR-
BT) with or without extra beam radiation therapy (EBRT) or 
low dose rate BT (LDR-BT). The patients were followed up for 
various periods ranging from 12 to 54 months. The patients 
did not have any other severe diseases that may have affected 
HRQoL, and biochemical or clinical disease progression was 
not observed during this study period. 
 The indication for RRP, HDR-BT with or without EBRT and 
LDR-BT was limited to clinically localized PCa. In addition, 
we classified the localized PCa patients into three risk group, 
based on clinical T classification, GS and PSA, according to 
the D’Amico risk grouping (high-risk was defined as > cT2b, 
primary GS ≥ 8, or PSA > 20; low-risk was defined as < T2a, 
primary GS ≤ 6, or PSA ≤ 10; intermediate-risk was defined as 
other than high-risk or low-risk) [3].
 In the first phase of this study design, patients who received 
neo-adjuvant HT for more than four months or for whom ad-
juvant or salvage HT was started within one year after treat-
ment were excluded from this study because of the significant 
influence of how the HT therapy would obscure the subject 
patients’ evaluations of their primary therapies. Two low-risk 
patients who selected active surveillance were also excluded 
from this study because of the very small population that they 
represented.
 HT was performed in metastatic PCa patients who were as-
ymptomatic for metastatic PCa and in patients over 75 years 
with clinically localized PCa. 
 RRP was performed in cases of localized PCa in low- or 
intermediate-risk patients. All except one patient (76 years) 
were less than 75 years. The nerve-sparing (NS) technique 
was performed if the patients wanted to preserve sexual func-
tion. The indications for NS depended on preoperative fac-
tors, such as primary GS and the number of positive biopsy 
cores and intraoperative factors. 
 HDR-BT with EBRT (40–46 Gy) was recommended and 
performed in high-risk and intermediate-risk patients. HDR-
BT monotherapy was recommended and performed in the 
low-risk group and in part of the intermediate-risk group. 
Age was not taken into consideration if performance status 
was good. Neo-adjuvant HT was performed in some patients 
who were anxious about the progression of the disease while 
awaiting treatment. HDR-BT using 192Ir in 2 doses of 9.5 Gy 
each within 24 hours for a total of 19 Gy or 3 doses of 6.0 Gy 
each within 24 hours, a total of 18 Gy. HDR-BT was performed 
by inserting 10 to 12 applicator needles into the prostate us-
ing the transperineal approach. The application needles re-
mained inserted during the 24-hour irradiation period.
 LDR-BT was recommended and performed in low- and 
intermediate-risk patients. Age was not taken into consider-
ation if the performance status was good. Patients treated with 
LDR-BT received about 140 to 160 Gy to the prostate with a 125I 
seed using a modified peripheral loading technique via the 
transrectal ultrasound-guided transperineal approach. We 
performed LDR-BT by the preplanning method.
 We measured general HRQoL using the Medical Outcomes 
Study 36-Item Short Form (SF-36) [4] and cancer-specific 
HRQoL using the functional assessment of cancer therapy-
general (FACT-G) [5]. PCa-specific HRQoL was measured 
using the FACT-prostate (FACT-P) [6], International Prostate 
Symptom Score (IPSS) [7], and International Index of Erectile 
Function-5 (IIEF-5) [8]. 
 SF-36 contains 36 items covering eight domains of HRQoL 
as follows: physical functioning (PF), role limitations because 
of physical health problems (RP), bodily pain (BP), general 
health (GH), vitality (VT), social functioning (SF), role limita-
tions caused by emotional problems (RE), and mental health 
(MH). A score ranging from 0 (worst) to 100 (best) was calcu-
lated for each domain. 
 All patients were informed of their cancer diagnosis before 
being given the HRQoL questionnaires. Questionnaires were 
administered at four points in time: the baseline survey was 
before treatment: and follow-up surveys were performed 3, 6, 
and 12 months after treatment. In this study, we used the self-
reported questionnaire method and asked patients to fill it 
out in the hospital.
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 After more than one year had elapsed since the commence-
ment of treatment, the patients were sent two questions by 
mail with regard to treatment satisfaction. One question was 
“How do you feel about your treatment?” The responses in-
cluded delighted, pleased, mostly satisfied, mixed, unhappy, 
and other. The second question was “Would you undergo the 
same treatment again if you had the chance?” They were given 
the response options of definitely yes, probably yes, probably 
not, or definitely not. These questions were based on a previ-
ous report by Hoffman et al. [9]. Inappropriate answers (mul-
tiple answers or blank answers) were excluded from the evalu-
ation. All data are shown as the mean (standard deviation) or 
median (range). Patients’ background data and HRQoL scores 
were tested by one-way analysis of variance in the four groups. 
In two groups, age was analyzed by the Scheffe test, and other 
data items were analyzed by the Dunn test. Significance was 
defined as P<0.05. 
RESULTS
The surveys were performed in 19, 31, 25, and 21 cases of HT, 
RRP, and HDR-BT with or without EBRT, and LDR-BT, respec-
tively. The backgrounds of each group are shown in Table 1. 
Age was significantly higher in HT than in the other groups 
(P < 0.01). In the clinical stage, the T category showed signifi-
cant differences between HT and RRP and between HT and 
LDR-BT (HT vs. RRP, HT vs. LDR-BT, P < 0.001). When we 
categorized the data according to GS into three groupings, 
< 6, 7, and > 8, significant differences were recognized be-
tween HT and RRP, between HT and HDR-BT, and between 
Table 1. Patient characteristics
Characteristic HT (n=19) RRP (n=31) HDR-BT (n=25) LDR-BT (n=21) P-value
Age (yr)
Mean±SD 74.9±7.1 66.7±5.0 67.0±5.0 66.4±7.0 <0.01a)
Median (range) 75 (58–86) 66 (58–76) 66 (58–77) 66 (50–79) <0.01a)
T category <0.001b)
T1c 6 21 13 16
T2a 1 8 7 5
T2b 1 0 4 0
T3a 0 1 2 0
T3b 0 1 0 0
T4 1 0 0 0
Tx N>0 or M>0 10 0 0 0
Metastases lesions (n) Bone (4), LN (3), bone & LN (3)
Gleason score <0.001c)
≤6 3 16 17 14
7 11 15 7 7
≥8 5 0 1 0
Initial PSA (ng/mL) <0.001c)
Mean±SD 208.2±305.7 6.8±5.1 8.0±3.2 6.1±2.1
Median (range) 122.9 (4.1–1018.4) 5.5 (2.2–29.8) 7.2 (4.1–13.2) 5.5 (2.1–10.4)
≤10 7 16 17 14
>10, ≤20 2 15 7 7
>20 10 0 1 0
D'Amico risk classification
Low 3 16 9 12 NSd)
Intermediate 5 15 10 9
High 11 0 6 0
Neoadjuvant hormone therapy (0–3 mo) 13 16 3
Nerve-sparing (bilateral) 2
Nerve-sparing (unilateral) 5
Nerve-sparing (unknown) 7
ERBT 17
HT, hormone therapy; RRP, radical retropubic prostatectomy; HDR-BT, high dose rate brachytherapy; LDR-BT, low dose rate brachytherapy; LN, lymph 
node; PSA, prostate-specific antigen; SD, standard deviation; NS, not significant; ERBT, extra beam radiotherapy.
a)Scheffe test; HT vs. RRP, HT vs. HDR-BT, HT vs. LDR-BT. b)Dunn test; HT vs. RRP, HT vs. LDR-BT. C)Dunn test; HT vs. RRP, HT vs. HDR-BT, HT vs. LDR-BT. 
d)Dunn test.
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Fig. 1. Effects of four treatments on each domain score of SF-36 in patients with prostate cancer. PF, physical functioning; RP, role limi-
tations because of physical health problems; BP, bodily pain; GH, general health; VT, vitality; SF, social functioning; RE, role limitations 
because of emotional problems; MH, mental health; HT, hormone therapy; RRP, radical retropubic prostatectomy; HDR-BT, high dose 
rate brachytherapy; LDR-BT, low dose rate brachytherapy; ANOVA, analysis of variance.
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HT and LDR-BT (HT vs. RRP, HT vs. HDR-BT, HT vs. LDR-BT, 
P < 0.001). The PSA scores for the HT cases were significantly 
higher than those for the other groups (P < 0.01). D’Amico 
Risk Classification showed that the HDR-BT group included 
six high-risk patients. The HT group contained one high-risk 
patient, but there were no significant differences among the 
four groups.
 Figs. 1 and 2 show the data of SF-36, FACT-G, FACT-P, IPSS, 
and IIEF-5. General and cancer-specific HRQoL measured 
by SF-36 and FACT-G showed little change when the base-
line and the 12-month results in each group were compared. 
In the HT group, SF-36 and FACT-G tended to show lower 
scores than in the other treatment groups before treatment, 
particularly RP and VT (RP, HT vs. LDR-BT, P < 0.05; VT, 
HT vs. RRP, P <0.05). In the RRP group, all SF-36 QoL scores 
at three months were worse than the baseline scores were. 
However, these scores showed recovery in the responses to 
the questionnaire at 12 months. In particular, PF, RP, SF, and 
RE showed significant improvement between 3 months and 
12 months. In the RRP group, the IIEF-5 scores were worse 
at six months, and recovery was not indicated in responses 
Table 2. Patient satisfaction
How do you feel about your treatment
HT RRP HDR-BT LDR-BT
Delighted 1 6 3 5
Pleased 10 12 8 12
Mostly satisfied 0 1 7 2
Mixed 3 6 4 1
Unhappy 0 0 0 0
Another 0 1 0 0
Satisfaction/total, n (%) 11/14 (79) 19/26 (73) 18/22 (82) 19/20 (95)
HT, hormone therapy; RRP, radical retropubic prostatectomy; HDR-BT, 
high dose rate brachytherapy; LDR-BT, low dose rate brachytherapy.
Dunn test: not significant.
Would you take the same treatment again if you had the chance?
HT RRP HDR-BT LDR-BT
Definitely yes 2 3 3 5
Probably yes 8 15 11 9
Not 3 4 7 4
Yes/total, n (%) 10/13 (77) 18/22 (82) 14/21 (67) 14/18 (78)
HT, hormone therapy; RRP, radical retropubic prostatectomy; HDR-BT, 
high dose rate brachytherapy; LDR-BT, low dose rate brachytherapy.
Dunn test: not significant.
Fig. 2. Effects of the four treatments on scores of functional assessment of cancer therapy-general (FACT-G), FACT-prostate (FACT-P), 
International Prostate Symptom Score (IPSS), and International Index of Erectile Function-5 (IIEF-5) in patients with prostate cancer. 
HT, hormone therapy; RRP, radical retropubic prostatectomy; HDR-BT, high dose rate brachytherapy; LDR-BT, low dose rate brachy-
therapy; ANOVA, analysis of variance.
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to the questionnaire at 12 months (pre vs. 3 months, pre vs. 6 
months, pre vs. 12 months, P<0.0001). In the HDR-BT group 
and LDR-BT group, IIEF-5 scores did not show a significant 
decrease. In the LDR-BT group, the disease-specific HRQoL, 
FACT-P, IPSS, and IIEF-5 scores were better than the base-
line scores in the other groups were (FACT-P, LDR-BT vs. HT, 
P=0.019; LDR-BT vs. HDR-BT, P=0.02; IIEF-5, LDR-BT vs. HT, 
P = 0.012). 
 Satisfaction with treatment selection was good in most 
cases (Table 2). The RRP group showed lower satisfaction 
(73%) than the other groups did, but this was not significant. 
The HDR-BT group gave a lower score (66%) than the other 
groups did (Table 2), in response to the question, “Would you 
undergo the same treatment again if you had the chance?” 
However, this difference was not significant.
DISCUSSION
Standard treatment for localized PCa traditionally involves 
radical prostatectomy and EBRT. However, HDR-BT with 192Ir 
and LDR-BT using 103Pd or 125I have recently been adopted 
around the world as minimally invasive treatment methods 
[1]. Moreover, HT promotes long-term survival in cases of low 
T stage, low grade GS, low PSA, and in patients showing good 
response to treatment [2].
 As excellent treatment outcomes have become more and 
more common regardless of the method of treatment chosen, 
subjective evaluation by patients, such as the HRQoL and pa-
tient satisfaction after treatment, have become as important 
as objective indices, such as overall survival or disease-free 
survival.
 In our institution, the selection of PCa treatments is deter-
mined by discussion between the patient and doctor. How-
ever, HRQoL and patients’ satisfaction after treatment had 
not been evaluated clearly. Our institution has four primary 
treatments for PCa: HT, RRP, and two types of BT (HDR-BT 
and LDR-BT). Although several reports have compared the 
QoL of two or three different PCa treatments [10-12], to our 
knowledge, this is the first report comparing the effects of 
four different treatments on HRQoL and satisfaction in PCa 
patients in the same period at one institution.
 The findings of our study are summarized as follows. Com-
parison of the baseline scores and 12-month results showed 
little change in general and cancer-specific HRQoL in all 
groups. The results specific to each group showed that in the 
HT groups, general, cancer-specific, and PCa-specific HRQoL 
scores did not change remarkably during the observation 
period. Because this was not a randomized study, and the 
patients in the HT group were significantly older than those 
in the other groups were, the original IIEF-5 scores were low 
in higher ages, and the influence of HT on sexual function re-
mained unchanged.
 The RRP group showed significant differences in the SF-
36 domains of PF, RP, SF, and RE between 3 and 12 months 
postoperatively. This group indicated a greater sense of intru-
siveness by the treatment than other treatment groups did. 
IIEF-5 was significantly decreased compared with the other 
groups, and did not show improvement within 12 months. 
In this study, definite NS operation was performed on only 
seven patients (Table 1). However, definite differences were 
observed between the NS group and the non-NS group (data 
not shown). Several responses to the questionnaire said that 
sexual dysfunction was noted as a postoperative adverse 
event [13,14]. The NS group reported that it took more than 
two years for the recovery of sexual function [15,16]. There-
fore, it is difficult to improve sexual function within less than 
one year postoperatively, even in patients treated by the NS 
technique. In our study population, the RRP group did not 
show an increase in IPSS. Although some patients might have 
suffered from degradation of urinary function, this fact may 
not have been reflected by the IPSS score, because the ques-
tions were designed specifically to evaluate symptoms of be-
nign prostatic hyperplasia. This is because the IPSS does not 
specify stress incontinence [7,11].
 In both BT groups, the SF-36 data showed no significant 
differences between baseline and 12 months. Thus, both 
kinds of BT treatments seemed less intrusive than RRP did. 
On the other hand, the findings showed that patients with 
good sexual and urinary function tended to choose LDR-BT. 
Furthermore, the LDR-BT group showed significant IPSS 
degradation within three months. However, the values im-
proved to baseline levels within 12 months. Both kinds of BT 
are considered minimally invasive treatments in comparison 
with RRP and EBRT [3,17-19]. Hall et al. [20] reported that for 
40% of patients, a favorable side-effect profile was the main 
motivation in selecting BT. Both kinds of BT appeared to have 
clear advantages over RRP in terms of urinary and sexual 
function. However, transient irritative and obstructive symp-
toms were reported [17,21,22]. Desai examined urination 
condition after LDR-BT based on IPSS score, and reported 
that IPSS score was poorest one month after treatment and 
improved gradually thereafter [23]. Our study showed similar 
results [3,23]. In the present study, patients with good void-
ing conditions tended to select the LDR-BT treatment and 
appeared to experience transient bladder irritability and ob-
struction after treatment. 
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 In this study, we evaluated patient satisfaction more than 
one year after treatment following QoL evaluations for each 
treatment. The RRP group showed a low level of satisfaction 
with the treatment results (73%). Our data were similar to 
those of Hoffman et al. [9], who reported that patients treated 
with radical prostatectomy had lower satisfaction scores than 
those treated with HT and radiation therapy. However, our 
data showed no significant differences from other treatment 
groups, and almost all had good satisfaction scores. We be-
lieve that complete cure-related satisfaction exceeded QoL-
related dissatisfaction. Interestingly, although not significant, 
the HDR-BT group’s response to the question, “Would you 
undergo the same treatment again if you had the chance?” 
ranked the lowest in the evaluation. This may be because of 
the requirement for the patients to rest for 24 hours with nee-
dles penetrating the perineal region, combined with postop-
erative temporary dysuria, which resulted in more discomfort 
in the perioperative period than the other treatment groups 
experienced [3]. No previous studies comparing periopera-
tive satisfaction with BT and RRP. Therefore, ours findings are 
significant.
 We emphasize the following points regarding the design of 
our study. First, this was not a randomized study, but a pro-
spective longitudinal comparative study in the same period 
at one institution. Second, the results were obtained using a 
self-reported questionnaire. There was likely to be less bias in 
these results. As Namiki and Arai [17] suggested, a patient’s 
self-reported symptoms are likely to differ from those recorded 
by his doctor, so it is better whenever possible to have patients 
fill out self-reported questionnaires. Third, in this study, we 
evaluated not only HRQoL scores but also patient satisfaction 
with treatment. More than 70% of patients were satisfied with 
the treatments they received.
 On the other hand, our study had several limitations. First, 
at 96 patients, the sample was small. The significance of this 
number is questionable in the comparisons of each sub-group. 
Nevertheless, we believe that this data illuminated the ten-
dency for each group’s QoL and patient satisfaction. Second, 
because this was a prospective study and not a random study, 
the average ages in the HT and PSA groups were higher than 
in the other groups, and the HT group included patients with 
metastasis. Therefore, it is difficult to compare the HT group 
and the other groups. However, in this study in the HT group, 
general conditions were good and exhibited no severe com-
plications. Hence, we believe that our findings could be useful 
in comparing HT group patients without metastasis and other 
groups in the future. Third, when evaluating patient satisfac-
tion, blank answers or multiple answers were excluded from 
the data collection. Because this study used a self-reported 
questionnaire, there may have been some bias, so improve-
ment of the data collection method is necessary. Employing 
a research coordinator to get accurate data seems best [13]. 
Fourth, in this QoL investigation there were no definite ques-
tions regarding stress incontinence for RRP, gross hematuria, 
melena and diarrhea for BT, or for climacteric symptoms, 
such as hot flashes and gynecomastia for HT. Therefore, it was 
impossible to evaluate QoL accurately for all four treatments 
[13]. Although there were 50 questions in the questionnaire, 
future evaluations using the expanded PCa index composite 
(EPIC), which was developed from the University of Califor-
nia, Los Angeles Prostate Cancer Index, would render more 
significant results because the EPIC includes questions about 
voiding irritability, incontinence, rectum irritability, and 
complications in endocrine treatment [15].
 This study examined HRQoL and patient satisfaction with 
four different treatments for PCa. Each treatment had charac-
teristic findings, but the decrease of IIEF-5 in the RRP group 
was especially remarkable. The HDR- and LDR-BT groups 
were superior with regard to sexual function.
 However, interestingly, the responses showed that most 
patients who had received a particular treatment were satis-
fied with their treatment and that they would choose the 
same treatment again, even if another treatment were more 
highly recommended. Most patients should be able to select 
a particular treatment based on their feelings, view of life, and 
background. Therefore, it is just as important—perhaps even 
more important—for doctors to know how to monitor and 
diminish potential adverse events in whatever treatment the 
patient chooses as it is to determine which treatment method 
is the best from the physician’s point of view.
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